Mitigating diabetes associated with reactive oxygen species (ROS) and protein aggregation through pharmacological interventions (original) (raw)
* Corresponding authors
a Division of Biological and Environmental Sciences and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia
E-mail: mariusz.jaremko@kaust.edu.sa
b Department of Biology, College of Science, Imam Abdulrahman Bin Faisal University (IAU), Dammam 31441-1982, Saudi Arabia
c Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
d Department of Materials Science and Technology, University of Crete, 70013 Heraklion, Crete, Greece
e Institute of Electronic Structure and Laser (IESL) FORTH, 70013 Heraklion, Crete, Greece
f Department of Population Health, Division of Environmental Health and Occupational Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 7, Wroclaw, Poland
Abstract
Diabetes mellitus, a complex metabolic disorder, presents a growing global health challenge. In 2021, there were 529 million diabetics worldwide. At the super-regional level, Oceania, the Middle East, and North Africa had the highest age-standardized rates. The majority of cases of diabetes in 2021 (>90.0%) were type 2 diabetes, which is largely indicative of the prevalence of diabetes in general, particularly in older adults (K. L. Ong, et al., Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021, Lancet, 2023, 402(10397), 203–234). Nowadays, slowing the progression of diabetic complications is the only effective way to manage diabetes with the available therapeutic options. However, novel biomarkers and treatments are urgently needed to control cytokine secretion, advanced glycation end products (AGEs) production, vascular inflammatory effects, and cellular death. Emerging research has highlighted the intricate interplay between reactive oxygen species (ROS) and protein aggregation in the pathogenesis of diabetes. In this scenario, the main aim of this paper is to provide a comprehensive review of the current understanding of the molecular mechanisms underlying ROS-induced cellular damage and protein aggregation, specifically focusing on their contribution to diabetes development. The role of ROS as key mediators of oxidative stress in diabetes is discussed, emphasizing their impact on cellular components and signaling. Additionally, the involvement of protein aggregation in impairing cellular function and insulin signaling is explored. The synergistic effects of ROS and protein aggregation in promoting β-cell dysfunction and insulin resistance are examined, shedding light on potential targets for therapeutic intervention.
- This article is part of the themed collections:2024 Reviews in RSC Advances and 2024 RSC Advances Popular Advances Collection
This article is Open Access
Please wait while we load your content... Something went wrong. Try again?
Article information
DOI
https://doi.org/10.1039/D4RA02349H
Article type
Review Article
Submitted
27 Mar 2024
Accepted
22 May 2024
First published
29 May 2024
This article is Open Access
Download Citation
RSC Adv., 2024,14, 17448-17460
Permissions
Mitigating diabetes associated with reactive oxygen species (ROS) and protein aggregation through pharmacological interventions
G. Bennici, H. Almahasheer, M. Alghrably, D. Valensin, A. Kola, C. Kokotidou, J. Lachowicz and M. Jaremko,RSC Adv., 2024, 14, 17448DOI: 10.1039/D4RA02349H
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.
To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.